Zimmer Biomet Reports Q3 2026 Earnings & Raises Full-Year Guidance
ZIMMER BIOMET HOLDINGS, INC.
Subscribe to track ZBH
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
š Zimmer Biomet Holdings (NYSE: ZBH) Q3 2026 Earnings Release
ā¢ Net Sales: $2.063B (+3.1% reported, +3.7% constant currency) ā¢ GAAP Diluted EPS: $1.00 (-13.8% YoY) ā¢ Adjusted Diluted EPS: $1.90 (flat YoY) ā¢ Operating Cash Flow: $560.0M | Free Cash Flow: $372.4M ā¢ Guidance: Raised full-year organic constant-currency sales growth and adjusted EPS outlook.
Comprehensive Analysis
Executive Summary
On November 4, 2026, Zimmer Biomet Holdings, Inc. filed a Form 8-K under Item 2.02 (Results of Operations and Financial Condition) announcing financial results for the third quarter ended September 30, 2026, and updating full-year 2026 guidance.
Key Financial Highlights
- Net Sales: $2.063 billion, an increase of 3.1% on a reported basis and 3.7% on a constant currency basis compared to Q3 2025.
- Earnings Performance:
- GAAP Net Earnings: $191.6 million ($1.00 diluted EPS), down 13.8% year-over-year.
- Adjusted Net Earnings: $362.8 million ($1.90 adjusted diluted EPS), matching the prior-year quarter.
- Cash Flow: Generated $560.0 million in operating cash flow and $372.4 million in free cash flow during Q3 2026.
- Segment Drivers: Management highlighted high-single-digit to double-digit growth across its Hips, S.E.T., Technology & Data, Bone Cement, and Surgical franchises.
- Guidance Update: Based on solid operational execution and broad-based demand, the company raised its full-year 2026 organic constant-currency sales growth and adjusted EPS guidance.
Corporate & Commercial Updates
- Announced commercial leadership promotions (Gary Campbell, Brian Hatcher, Bradley Kessler) to drive U.S. transformation.
- Extended a multi-year limited exclusive distribution and supply agreement with THINK Surgical to enhance robotics offerings.
- Opened a new Zimmer Biomet Institute education and training facility in Charlotte, North Carolina.
- Expanded the extremities portfolio with the launches of the MegalodonĀ® Dynamic Compression System and SmartShotĀ® Marrow Access Device.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.